Detalles de la búsqueda
1.
Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
J Hepatol
; 2024 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428644
2.
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals.
Clin Gastroenterol Hepatol
; 22(5): 1037-1047.e9, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38154729
3.
Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial.
Ann Intern Med
; 176(1): 10-21, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36508737
4.
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
J Hepatol
; 79(2): 277-286, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37088311
5.
Validation of scores of PRO-C3 to predict liver-related events in alcohol-related liver disease.
Liver Int
; 43(7): 1486-1496, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37183542
6.
Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation-related markers.
Liver Int
; 43(12): 2680-2691, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37592403
7.
Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO-C3).
Liver Int
; 42(1): 92-101, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34845832
8.
Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease.
Gut
; 2023 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37344168
9.
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.
BMJ Open
; 14(2): e079309, 2024 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38355195
10.
Infections increase the risk of decompensation and death in patients with early alcohol-related liver disease.
JHEP Rep
; 6(4): 101016, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38486819
11.
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
Lancet Gastroenterol Hepatol
; 9(3): 218-228, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38218202
12.
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Gastroenterol Hepatol
; 8(6): 523-532, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36893774
13.
Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis.
JHEP Rep
; 3(3): 100287, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-34041469
14.
Corrigendum to 'Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis' [JHEP Reports 3 (2021) 100287].
JHEP Rep
; 3(5): 100353, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34693237
15.
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication.
JHEP Rep
; 3(5): 100325, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34401690
16.
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease - Authors' reply.
Lancet Gastroenterol Hepatol
; 8(7): 604, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37301207
17.
MetALD: new opportunities to understand the role of alcohol in steatotic liver disease.
Lancet Gastroenterol Hepatol
; 8(10): 866-868, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567208
Resultados
1 -
17
de 17
1
Próxima >
>>